Endometrial response in estrogen replacement therapy quarterly combined with a progestogen

Maturitas

Volumn 24, Issue 1-2, 1996, Pages 63-71

  Boerrigter, Peter J ^a,b   Van De Weijer, Peter H M ^a   Baak, Jan P A ^a   Fox, Harold ^c   Haspels, Ary A ^d   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Manchester ^*  (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Endometrium; HRT; Progestin; Quarterly regimen

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; GESTODENE;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG SAFETY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CYTOLOGY; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN TISSUE; MENSTRUAL CYCLE; PAPANICOLAOU TEST; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VAGINA BLEEDING;

EID: 0029950686     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)01020-3     Document Type: Article

References (22)

1. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporosis Int 1990; 1: 7-13.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63.
3. Whitehead M, Lobo RA. Consensus conference: progestagen use in postmenopausal women. Lancet 1988; 2: 1243-1244.
4. Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989: 161: 1854-1858.
5. Wren BG, Brown L. Compliance with hormonal replacement therapy. Maturitas 1991; 13: 17-21.
6. Marslew U, Riis BJ, Christiansen C. Bleeding patterns during continuous estrogen-progestogen therapy. Am J Obstet Gyneeol 1991; 164: 1163-1168.
7. Matsson LA, Cullberg G, Samsioe G. Evaluation of a continuous estrogen-progestogen regimen for climacteric complaints. Maturitas 1982; 4: 95-102.
8. Magos AL, Brincat M, O'Dowd T, Wardle PJ, Schlesinger P, Studd JWW. Endometrial and menstrual response to subcutaneous oestradiol and testosterone implants and continuous oral progestogen therapy in post-menopausal women. Maturitas 1985; 7: 297-302.
9. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75(4 Suppl): 59S-76S.
10. Schiif I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982; 37: 79-82.
11. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693-700.
12. Williams DB, Voigt BJ, Fu YS, Schoenfeld MJ, Judd HL. Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol 1994; 84: 787-793.
13. Hirvonen E, Salmi T, Puolakka J, Heikkinen J, Granfors E, Hulkko S et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995; 21: 39-44.
14. Fleischer AC, Mendelson EB, Böhm-Vélez M, Entmann SS. Transvaginal and transabdominal sonography of the endometrium. Semin Ultrasound CT MR1 1988; 9: 81-101.
15. Barentsen R, Groeneveld FPMJ, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 203-207.
16. Whitehead MI. Prevention of endomctrial abnormalities. In: Greenblalt RB. ed. A modern approach to the perimenopausal years. New Developments in Biosciences, 2. Berlin: Walter de Gruyter, 1986; 189-206.
17. Gambrell RD Jr. Prevention of endometrial cancer with progestogens. Maturitas 1986; 8: 159-168.
18. Kemp JF, Fryer JA, Baber RJ. An alternative regimen of hormone replacement therapy to improve patient compliance. Aust NZ J Obstet Gynaecol 1989; 29: 66-69.
19. David A, Reif A, Weissglas L. Cyclic and combined hormonal treatment regimen in postmenopausal women: hysteroscopic findings. In: Fioretti P et al., eds. Post-menopausal Hormonal Therapy: Benefits and Risks. New York: Raven Press, 1987; 77-81.
20. Baak JPA, Wisse-Brekelmans ECM, Fleege JC, van der Putten HWHM, Bezemer PD. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Path Res Pract 1992; 188: 856-859.
21. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 1985; 56: 403-412.
22. Padwick ML, Pryse-Davies J, Whitehead MI. A simple method for determining the optimal dosage of progestin in postmenopausal women receiving estrogens. New Engl J Med 1986; 315: 930-934.